Investor Information

Transforming Drug Discovery with AI: Cost-Effective, Time-Saving, and Profitable.

Discovery

Why Delta4?

We leverage our proprietary AI-powered platform to help clients uncover undetected relationships between drugs with known safety profiles and diseases to identify new indications.
Our platform, Hyper-C, transforms the traditional R&D process by reducing costs, enhancing decision-making, and increasing success rates to bring new therapies to market faster, safer, and at a lower cost than ever before.

Our Service

What We Can Do

The AI drug discovery process can encompass many different capabilities. While drug indication expansion is the bulk of what we focus on, there are many things that Delta4 is contracted to do for its clients. Below is a brief list of our capabilities.

Find new indication(s) for existing drugs
Find new drugs for a given indication
Confirm clients' research on new indication(s)
Generate strong Mechanism of Action (MoA) hypotheses
Provide specific background info on a drug effect and/or side effect
Provide insights on downstream consequences
Identify and rank disease-modifying drug targets
Propose prognostic and predictive target protein biomarkers

Development

Our Approach

At the heart of our drug development process is our in-silico platform – Hyper-C. Over 70 man-years of development have gone into creating a revolutionary platform that efficiently identifies undetected relationships between drug candidates and diseases at the chemical compound level.

Hyper-C achieves this through an iterative process where immense quantities of data from 15+ major data stores including biomedical literature, molecular modeling, clinical studies, investigations, clinical trials, etc. are analyzed against disease models. Utilizing its algorithmic intelligence Hyper-C efficiently identifies relationships between drugs and diseases. The result is a proposed shortlist of potential drug candidates that have survived countless rounds of in-silico testing.

Many other AI-enabled drug discovery platforms are akin to a black box in that the result(s) are not always understandable. Hyper-C provides a clear mechanism of action hypothesis and biomarkers for patient stratification. This allows our team to quickly work with and interpret the data. It also has the added benefit of making it easier to satisfy regulatory requirements.

Get To Know Us

Our Team

Delta4 is backed by a diverse team with an abundance of knowledge and experience in key fields. We are all passionately dedicated to discovering innovative and effective drugs to patients faster and more safely than ever before so that we can improve their health and quality of life.

Our Partners & Clients

It’s an honor and a privilege to be working with the best of the best!

We found Delta4’s approach very interesting and helpful. Therefore, we are convinced that your approach for an initial analysis of a new mode-of-action concept would greatly support our activities in indication expansion – in other words, it would save us a lot of time internally.

At 4P-Pharma, our foundation is based on scientific rationale. Delta4 has provided us with this essential foundation for our co-development project, enabling us to start from the mechanism of action in the disease. This approach allows us to more accurately and quickly identify and validate therapeutic targets, making our drug development process more efficient and focused.

The Delta4 team members are highly competent in big data network analyses both from the disease side and from the drug product and pharmacology side. Their methodology of marrying one with the other led us to new intellectual property.

This innovative methodology has enabled us to identify therapeutic targets that have never been described before for specific indications.

Thanks to DELTA4, we have been able to speed up the selection of preclinical models, that will allow us to effectively prove the beneficial effects of those drug candidates.

Their reporting is thorough and to the point. We highly recommend Delta4 as an AI partner for drug discovery and development.

...allowing us to progress in bringing new drugs to patients suffering from serious, untreated diseases.

Streamlining Transparency and Cooperation

Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.

“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com

Are you a member of Scientist.com? View Our Profile

Learn About Opportunities with Delta4

Reach out to us today to learn about investment options and how you can get involved with Delta4.